Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus acarbose added to insulin in adults with type 1 diabetes
ChiCTR1800019724Phase 4Not yet recruiting
- Sponsor
- Department of Endocrinology, the First Affiliated Hospital of Shantou University
- Start
- Nov 2018
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin and acarbose in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Department of Endocrinology, the First Affiliated Hospital of Shantou University. Primary endpoint: Mean amplitude of glycemic excursions. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
dapagliflozinacarbose
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ChiCTR1800019724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019724.